LEHI, UTAH / ACCESSWIRE / November 12, 2019 / Frelii, Inc. (OTC PINK:FRLI) ("Frelii" or the "Company"), a biotechnology company working to commercialize its patent-pending DNA gene sequencing ...
Presenting Author: Sharat Singh, PhD, Head of Research, Biora Therapeutics, Inc. About the BioJet™ Systemic Oral Delivery PlatformBiora's BioJet systemic oral therapeutics platform uses an ingestible ...
BEERSE, Belgium--(BUSINESS WIRE)--The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the European Commission (EC) has granted marketing authorisation for the expanded use of ...
Raanana, Israel, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal administrated ...
Biological role of TUSC3 in non-small-cell lung cancer. This is an ASCO Meeting Abstract from the 2018 ASCO Annual Meeting I. This abstract does not include a full text component.
Buccal drug delivery systems represent an innovative strategy for the administration of therapeutic agents via the oral mucosa. This approach bypasses the hepatic first‐pass metabolism, thereby ...
CARLSBAD, Calif.--(BUSINESS WIRE)--BriOri BioTech, an emerging pre-clinical stage biotech company focused on developing a pipeline of opiate-free topical pain medications, announces its patent for ...
TMB-003 is a locally delivered formulation of sitaxsentan, a highly selective endothelin receptor antagonist. The Food and Drug Administration (FDA) has granted Orphan Drug designation to TMB-003 ...
Dr. Singh will also participate in a panel discussion on June 19 at 8:45 AM titled “Uncovering Innovations in Peptide Drug Delivery & Formulation for Improved Bioavailability,” alongside ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results